Indomethacin

Generic Name: Indomethacin

Brand Names: Indocin, Tivorbex

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₆ClNO_₄

CAS Number: 53-86-1

Unique Ingredient Identifier: XXE1CET956

Background: Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-ace...

Indication: Oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
...

Associated Conditions: Acute Gouty Arthritis, Joint Pain, Moderate to Severe Osteoarthritis, Moderate to Severe Rheumatoid Arthritis, Moderate to severe ankylosing spondylitis, Myalgia, Patent Ductus Arteriosus (PDA), Acute Shoulder Pain

Associated Therapies: -

Clinical Trials

Cerebral near-infrared spectroscopy guided neonatal intensive care management for the

Article references focus on neonatal shock, cerebral blood flow, neurovascular coupling, and near-infrared spectroscopy in preterm infants, emphasizing risk factors, treatment guidelines, and outcomes.

nature.com

2 months ago

Early drug treatment in preterm patients with large patent ductus arteriosus at 28 weeks or ...

Various studies on patent ductus arteriosus (PDA) in preterm infants, including therapeutic strategies, pathophysiology, and treatment options, are referenced. Key trials and meta-analyses highlight the efficacy of non-intervention, ibuprofen, and paracetamol in managing PDA, with discussions on the implications of early treatment versus expectant management. The articles also cover systematic reviews, randomized controlled trials, and consensus guidelines for PDA closure procedures.

news.ohsu.edu

4 months ago

New drug combinations could improve therapies for breast cancer, other aggressive cancers

Oregon Health & Science University researchers discovered a treatment combo that slows cancer progression and reduces tumor growth in aggressive cancers like triple-negative breast cancer and mesothelioma.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy